Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
AVAILABLE
NCT07629401

Pre-approval Expanded Access of Retatrutide (LY3437943)

Sponsor: Eli Lilly and Company

View on ClinicalTrials.gov

Summary

Provide pre-approval single-patient expanded access of retatrutide (LY3437943), an investigational GLP-1/GIP/glucagon triple receptor agonist being studied for chronic weight management, for adults with severe obesity (body mass index \[BMI\] greater than or equal to \[≥\]35 kilogram per square meter \[kg/m²\] and at least two serious or life-threatening obesity-related complications who are refractory to the best approved therapy and are unable to participate in an ongoing clinical trial of retatrutide or a comparable investigational medicine.

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

EXPANDED_ACCESS

Enrollment

Not specified

Start Date

Not specified

Completion Date

Not specified

Last Updated

2026-08-06

Healthy Volunteers

Not specified

Interventions

DRUG

Retatrutide